Semarion
A University of Cambridge spin-out tackling unmet drug screening needs by combining materials engineering and cell biology.
About
Technology stack
detected 2026-06-15No comments yet. Be the first to share your take.
What does Semarion do?
Semarion develops SemaCyte® microcarriers, which are ultra-miniaturised, barcoded micro-wells that enable adherent cells to become assay-ready reagents. This technology allows for the multiplexing of cell models in standard liquid handling workflows, facilitating faster, more scalable, and comparable cell-based experiments for in vitro drug discovery. Semarion serves teams looking to generate better data and accelerate drug discovery by removing bottlenecks in adherent cell screening.
How much funding has Semarion raised?
Semarion has raised a total of $9M in funding. The most recent round on record is Funding Round.
Where is Semarion headquartered?
Semarion is headquartered in Cambridge, England, United Kingdom.
When was Semarion founded?
Semarion was founded in 2018.
What industry does Semarion operate in?
Semarion operates in Biotechnology, Drug Discovery, Materials Science, Life Sciences, Biotech, MedTech.
How many employees does Semarion have?
Semarion has approximately 12 people on record.